The Psychosomatic Pattern: Historical Parallels

ME/CFS is not the first disease to be dismissed as psychosomatic before its biological basis was established. A systematic review of the history of psychosomatic medicine reveals a recurring pattern across at least ten major diseases (ME/CFS Science 2021):

CautionSpeculation: Psychologization Lag and the Biomarker Threshold

Historical patterns suggest that the decline in psychologization after biomarker discovery is real but slow: peptic ulcer (Marshall 1984), SLE (LE cell 1948 → ANA standard), and multiple sclerosis (MRI introduction 1980s) each show a multi-decade lag between first compelling biological evidence and widespread clinical acceptance. A sufficiently specific biomarker (ANA for SLE, H. pylori for ulcer, MRI for MS) appears capable of reducing psychologization, but not instantaneously and not completely — some residual tendency to attribute symptoms to psychology persists even after a biomarker is available, particularly for female patients, atypical presentations, and patients who test negative for standard markers despite having the disease. The precise duration of the lag and how well it generalises across different diseases are unknown; the three cases are illustrative, not a formal statistical sample.

This pattern has implications for ME/CFS. Any validated biomarker would likely reduce but not eliminate psychologization, following a lag whose duration cannot be predicted from three historical cases. Psychologization may also decline without a single definitive biomarker if a convergent body of objective physiological abnormalities reaches clinical consensus — a trajectory ME/CFS may already be on, given the accumulation of immunological, metabolic, and autonomic findings documented in the pathophysiology chapters. The post-COVID Long COVID connection may accelerate this trajectory through a “legitimacy spillover”: clinicians and researchers who develop LC and experience PEM firsthand are less likely to attribute it to psychological causes.

Fibromyalgia provides a counter-example: despite accumulating biomarker evidence (small fiber neuropathy, neuroinflammation by PET, central sensitization by fMRI), the condition remains heavily psychologized. Observational differences that may contribute include the absence of a clear post-infectious trigger cohort analogous to LC, the 80% female patient skew, and the lack of a single decisive biomarker. This is a comparison drawn after the fact, not a prediction — whether ME/CFS follows the trajectory of MS/SLE (partial decline in psychologization) or fibromyalgia (persistent psychologization) is unknown and depends on factors beyond biomarker discovery alone, including institutional, political, and cultural dynamics.

(Certainty: 0.40. The core observation (biomarker discovery tends to reduce psychologization) is grounded in historical cases but the quantitative features (lag duration, residue rate, fibromyalgia comparison) are extrapolated from a small, non-systematic set of examples and should be treated as qualitative pattern recognition, not quantitative prediction. Origin: brainstorm.)

References

ME/CFS Science. 2021. “A New Blog Series on the Dark History of Psychosomatic Medicine.” 2021. https://mecfsscience.org/history-of-psychosomatic-medicine/.